Uracil-induced calculi and carcinogenesis in the urinary bladder of rats treated simultaneously with N-butyl-N-(4-hydroxybutyl)nitrosamine. 1991

M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
First Department of Pathology, Nagoya City University Medical School, Japan.

Urinary bladder carcinogenicity of uracil and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in combination was investigated in male F344 rats. Two experiments were performed: in the first animals were treated with 3.0, 1.0 and 0.3% uracil in the diet and/or 0.005% BBN in the drinking water for 36 weeks followed by a 4 week period without chemicals, the total observation time being 40 weeks; in the second rats received 3.0% uracil in the diet or 0.05% BBN in the drinking water for 4 weeks. In the first experiment, a markedly high incidence of carcinomas was observed in the urinary bladder with both 3.0% uracil alone (11/15, 73%) and 3.0% uracil plus 0.005% BBN (18/20, 90%) treatments. The multiplicity, i.e. numbers of carcinomas induced per 10 cm of basement membrane, was significantly higher with the latter treatment (P less than 0.05), as were proliferative lesions in the renal pelvis. Stone formation was observed in all 3.0% uracil treatment animals. In the second experiment, prostaglandin E2 levels in bladder tissue of uracil-treated animals proved to be significantly higher than in BBN-treated or untreated animals. Thus, the results clearly indicated that calculi associated with 3.0% uracil ingestion can themselves cause carcinoma development in the urinary bladder, while also acting as a potent co-carcinogen agent for BBN carcinogenesis.

UI MeSH Term Description Entries
D008297 Male Males
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001744 Urinary Bladder Calculi Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths. Urinary Bladder Stones,Vesical Calculi,Bladder Calculi,Bladder Stones,Calculi of Urinary Bladder,Cystoliths,Bladder Calculi, Urinary,Bladder Calculus,Bladder Calculus, Urinary,Bladder Stone,Bladder Stone, Urinary,Bladder Stones, Urinary,Calculi, Bladder,Calculi, Urinary Bladder,Calculi, Vesical,Calculus, Bladder,Calculus, Urinary Bladder,Calculus, Vesical,Cystolith,Stone, Bladder,Stone, Urinary Bladder,Stones, Bladder,Stones, Urinary Bladder,Urinary Bladder Calculus,Urinary Bladder Stone,Vesical Calculus
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002085 Butylhydroxybutylnitrosamine A substituted carcinogenic nitrosamine. Butylbutanolnitrosamine,N-Butyl-N-(4-hydroxybutyl)nitrosamine,N-Nitroso-N-butyl-(4-hydroxybutyl)amine,N-Nitrosobutyl-4-hydroxybutylamine,N Nitrosobutyl 4 hydroxybutylamine
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
August 1987, Journal of the National Cancer Institute,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
December 1987, Cancer research,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
January 1985, Journal of the National Cancer Institute,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
March 1982, Acta pathologica japonica,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
November 1996, Carcinogenesis,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
January 1984, Journal of cancer research and clinical oncology,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
January 1993, Journal of cancer research and clinical oncology,
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
January 2024, Methods in molecular biology (Clifton, N.J.),
M Okumura, and T Shirai, and S Tamano, and M Ito, and S Yamada, and S Fukushima
February 1977, Gan,
Copied contents to your clipboard!